Background & Aims

Gut microbiota influences the central nervous system via diverse gut-brain axes. Accumulating studies indicated that gut microbiota could undergo significant alterations in patients with chronic pain [1-3] and subsequently alter pain thresholds by affecting pain pathways [4]. We aimed to elucidate the potential interactions between gut microbiota and the pain descending pathway.

Methods

Functional magnetic resonance imaging (fMRI) was used to identify the affected pain pathways. Neural tracing combined with MiP-seq spatial omics were employed to determine the cell atlas in the affected pain pathway. Optogenetics, chemogenetics, in vivo electrophysiology, and behaviour tests were conducted to validate the interaction between gut microbiota and pain descending control.

Results

Depletion of microbiota or administration of probiotic candidate (Bacterium X) proved effective in mitigating pain in animal models of neuropathic pain. fMRI unveiled differences in primary somatosensory cortex (S1) activity in response to painful stimuli between mice with intact or depleted microbiota. Neural tracing showed that a subset of pyramidal neurons in layer 5 of the S1 establishes direct synaptic connections with neurons distributed in lamina 3 to 5 of spinal cord dorsal horn. Optogenetic stimulation of the descending pyramidal neurons altered the local field potential in the spinal cord and attenuated mechanical allodynia, indicating a descending pain inhibitory control from S1 to spinal cord. Further spatial transcriptomics determined the identities of the target cells receiving S1 output. Chemogenetic inhibition of the target cells diminished the excitability of spinal cord projection neurons and abolished the pain-alleviating effects observed with microbiota depletion.

Conclusions

Our study proposed that gut microbiota could shape S1-spinal cord descending pathway to modulate pain processing.

References

[1] A Minerbi, E Gonzalez, et al. Altered microbiome composition in individuals with fibromyalgia. Pain. 2019, 160(11): 2589-2602.
[2] M Clos-Garcia, N Andres-Marin et al., Gut microbiome and serum metabolome analyses indentify molecular biomarkers and altered glutamate metabolism in fibromyalgia. EBioMedicine. 2019, 46: 499-511.
[3] Y Chu, S Sun et al. Metagenomics analysis revealed the potential role of gut microbiome in gout. NPJ Biofilms Microbiomes. 2021, 7(1):66.
[4] R Guo, LH Chen et al. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Br J Anaesth. 2019, 123(5): 637-654.

Presenting Author

Liu Xiaodong

Poster Authors

Xiaodong LIU

PhD

The Chinese University of Hong Kong

Lead Author

Yanjun Jiang

Mphil

The Chinese University of Hong Kong

Lead Author

Tingting Jin

PhD

The Chinese University of Hong Kong

Lead Author

Tak Vai Chan

PhD

The Chinese University of Hong Kong

Lead Author

Ka Kei Wu

PhD

The Chinese University of Hong Kong

Lead Author

Topics

  • Models: Chronic Pain - Neuropathic